Cost normalization for global capital projects benchmarking

Jiukun Dai, Stephen Mulva, Sung Joon Suk, Youngcheol Kang

Research output: Chapter in Book/Report/Conference proceedingConference contribution

6 Citations (Scopus)

Abstract

Globally, many large pharmaceutical and biotechnology companies invest significant amounts of money to build manufacturing and laboratory facilities. One common concern amongst these companies is whether or not these facilities are efficient in their design and their use of human and financial resources. The Construction Industry Institute (CII) has worked with 12 of these pharmaceutical and biotechnology companies over the past seven years to benchmark the performance of their capital projects. In order to benchmark absolute cost performance (e.g., dollars per square foot), the projects' costs need to be normalized to account for location, time and currency. However, no single cost index is available to meet this need of normalizing global facilities. As a result, CII and the companies developed a procedure using established cost indices to reliably compare the cost performance of capital projects from different companies. This paper also discusses the issues and challenges of normalizing the costs associated with pharmaceutical and biotechnology capital projects. This paper contributes to a better understanding of cost normalization amongst global capital projects.

Original languageEnglish
Title of host publicationConstruction Research Congress 2012
Subtitle of host publicationConstruction Challenges in a Flat World, Proceedings of the 2012 Construction Research Congress
Pages2400-2409
Number of pages10
DOIs
Publication statusPublished - 2012 Sep 19
EventConstruction Research Congress 2012: Construction Challenges in a Flat World - West Lafayette, IN, United States
Duration: 2012 May 212012 May 23

Publication series

NameConstruction Research Congress 2012: Construction Challenges in a Flat World, Proceedings of the 2012 Construction Research Congress

Other

OtherConstruction Research Congress 2012: Construction Challenges in a Flat World
CountryUnited States
CityWest Lafayette, IN
Period12/5/2112/5/23

Fingerprint

Benchmarking
Biotechnology
Costs
Drug products
Construction industry
Industry

All Science Journal Classification (ASJC) codes

  • Civil and Structural Engineering
  • Building and Construction

Cite this

Dai, J., Mulva, S., Suk, S. J., & Kang, Y. (2012). Cost normalization for global capital projects benchmarking. In Construction Research Congress 2012: Construction Challenges in a Flat World, Proceedings of the 2012 Construction Research Congress (pp. 2400-2409). (Construction Research Congress 2012: Construction Challenges in a Flat World, Proceedings of the 2012 Construction Research Congress). https://doi.org/10.1061/9780784412329.241
Dai, Jiukun ; Mulva, Stephen ; Suk, Sung Joon ; Kang, Youngcheol. / Cost normalization for global capital projects benchmarking. Construction Research Congress 2012: Construction Challenges in a Flat World, Proceedings of the 2012 Construction Research Congress. 2012. pp. 2400-2409 (Construction Research Congress 2012: Construction Challenges in a Flat World, Proceedings of the 2012 Construction Research Congress).
@inproceedings{b066578f3023448ea69cad5f85644125,
title = "Cost normalization for global capital projects benchmarking",
abstract = "Globally, many large pharmaceutical and biotechnology companies invest significant amounts of money to build manufacturing and laboratory facilities. One common concern amongst these companies is whether or not these facilities are efficient in their design and their use of human and financial resources. The Construction Industry Institute (CII) has worked with 12 of these pharmaceutical and biotechnology companies over the past seven years to benchmark the performance of their capital projects. In order to benchmark absolute cost performance (e.g., dollars per square foot), the projects' costs need to be normalized to account for location, time and currency. However, no single cost index is available to meet this need of normalizing global facilities. As a result, CII and the companies developed a procedure using established cost indices to reliably compare the cost performance of capital projects from different companies. This paper also discusses the issues and challenges of normalizing the costs associated with pharmaceutical and biotechnology capital projects. This paper contributes to a better understanding of cost normalization amongst global capital projects.",
author = "Jiukun Dai and Stephen Mulva and Suk, {Sung Joon} and Youngcheol Kang",
year = "2012",
month = "9",
day = "19",
doi = "10.1061/9780784412329.241",
language = "English",
isbn = "9780784412329",
series = "Construction Research Congress 2012: Construction Challenges in a Flat World, Proceedings of the 2012 Construction Research Congress",
pages = "2400--2409",
booktitle = "Construction Research Congress 2012",

}

Dai, J, Mulva, S, Suk, SJ & Kang, Y 2012, Cost normalization for global capital projects benchmarking. in Construction Research Congress 2012: Construction Challenges in a Flat World, Proceedings of the 2012 Construction Research Congress. Construction Research Congress 2012: Construction Challenges in a Flat World, Proceedings of the 2012 Construction Research Congress, pp. 2400-2409, Construction Research Congress 2012: Construction Challenges in a Flat World, West Lafayette, IN, United States, 12/5/21. https://doi.org/10.1061/9780784412329.241

Cost normalization for global capital projects benchmarking. / Dai, Jiukun; Mulva, Stephen; Suk, Sung Joon; Kang, Youngcheol.

Construction Research Congress 2012: Construction Challenges in a Flat World, Proceedings of the 2012 Construction Research Congress. 2012. p. 2400-2409 (Construction Research Congress 2012: Construction Challenges in a Flat World, Proceedings of the 2012 Construction Research Congress).

Research output: Chapter in Book/Report/Conference proceedingConference contribution

TY - GEN

T1 - Cost normalization for global capital projects benchmarking

AU - Dai, Jiukun

AU - Mulva, Stephen

AU - Suk, Sung Joon

AU - Kang, Youngcheol

PY - 2012/9/19

Y1 - 2012/9/19

N2 - Globally, many large pharmaceutical and biotechnology companies invest significant amounts of money to build manufacturing and laboratory facilities. One common concern amongst these companies is whether or not these facilities are efficient in their design and their use of human and financial resources. The Construction Industry Institute (CII) has worked with 12 of these pharmaceutical and biotechnology companies over the past seven years to benchmark the performance of their capital projects. In order to benchmark absolute cost performance (e.g., dollars per square foot), the projects' costs need to be normalized to account for location, time and currency. However, no single cost index is available to meet this need of normalizing global facilities. As a result, CII and the companies developed a procedure using established cost indices to reliably compare the cost performance of capital projects from different companies. This paper also discusses the issues and challenges of normalizing the costs associated with pharmaceutical and biotechnology capital projects. This paper contributes to a better understanding of cost normalization amongst global capital projects.

AB - Globally, many large pharmaceutical and biotechnology companies invest significant amounts of money to build manufacturing and laboratory facilities. One common concern amongst these companies is whether or not these facilities are efficient in their design and their use of human and financial resources. The Construction Industry Institute (CII) has worked with 12 of these pharmaceutical and biotechnology companies over the past seven years to benchmark the performance of their capital projects. In order to benchmark absolute cost performance (e.g., dollars per square foot), the projects' costs need to be normalized to account for location, time and currency. However, no single cost index is available to meet this need of normalizing global facilities. As a result, CII and the companies developed a procedure using established cost indices to reliably compare the cost performance of capital projects from different companies. This paper also discusses the issues and challenges of normalizing the costs associated with pharmaceutical and biotechnology capital projects. This paper contributes to a better understanding of cost normalization amongst global capital projects.

UR - http://www.scopus.com/inward/record.url?scp=84866258819&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866258819&partnerID=8YFLogxK

U2 - 10.1061/9780784412329.241

DO - 10.1061/9780784412329.241

M3 - Conference contribution

AN - SCOPUS:84866258819

SN - 9780784412329

T3 - Construction Research Congress 2012: Construction Challenges in a Flat World, Proceedings of the 2012 Construction Research Congress

SP - 2400

EP - 2409

BT - Construction Research Congress 2012

ER -

Dai J, Mulva S, Suk SJ, Kang Y. Cost normalization for global capital projects benchmarking. In Construction Research Congress 2012: Construction Challenges in a Flat World, Proceedings of the 2012 Construction Research Congress. 2012. p. 2400-2409. (Construction Research Congress 2012: Construction Challenges in a Flat World, Proceedings of the 2012 Construction Research Congress). https://doi.org/10.1061/9780784412329.241